Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
The mechanism: pre-workout IGF-1 primes the PI3K/Akt pathway before mechanical tension (the primary anabolic stimulus from training) activates mTOR
Capture LDL-C levels, statin history, ASCVD status, and specialist notes before the PA request goes out
Individuals with pre-existing proliferative or severe non-proliferative diabetic retinopathy represent the highest-risk population
Aging 5 , 576587 (2025)